Sprout Social Announces Appointment of Raina Moskowitz to Board of Directors

CHICAGO, Dec. 10, 2020 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social” or the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced that Raina Moskowitz, Chief Operations, Strategy and People Officer at Etsy, Inc., will be joining their board of directors, effective December 10, 2020.

“As Sprout expands our footprint within the industry, we’re excited to have Raina join our board,” said Justyn Howard, CEO of Sprout Social. “She brings deep experience across several disciplines, has a proven track record with world-class companies and is a perfect complement to our board of directors and leadership team.”

Raina oversees a number of functions to develop and enable Etsy’s strategy by delivering exceptional service and experiences for both employees and customers. Prior to joining Etsy in early 2018, Raina led U.S. customer marketing at American Express, and held multiple leadership roles in product, strategy and marketing. She is a graduate of the Wharton School at the University of Pennsylvania.

“Social is integral to every brand’s success, and Sprout’s deep understanding of customer needs allows them to unlock value for organizations of all sizes,” said Moskowitz. “I’m inspired by Justyn and his leadership team’s passion for building both a differentiated product and culture. I am excited to join the board as Sprout continues to create meaningful connections between people and brands.”

About Sprout Social

Sprout Social offers deep social media listening and analytics, social management, customer care, and advocacy solutions to more than 25,000 brands and agencies worldwide. Sprout’s suite of solutions supports every aspect of a cohesive social program and enables organizations of all sizes to extend their reach, amplify their brand and create the kind of real connection with their consumers that drives their businesses forward. Headquartered in Chicago, Sprout operates across major social and digital platforms, including Twitter, Facebook, Instagram, Pinterest, LinkedIn and Google.

Availability of Information on Sprout Social’s Website and Social Media Profiles

Investors and others should note that Sprout Social routinely announces material information to investors and the marketplace using U.S. Securities and Exchange Commission (SEC) filings, press releases, public conference calls, webcasts and the Sprout Social Investors website. We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public. While not all of the information that the Company posts to the Sprout Social Investors website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Sprout Social to review the information that it shares at the Investors link located at the bottom of the page on www.sproutsocial.com and to regularly follow our social media profiles. Users may automatically receive email alerts and other information about Sprout Social when enrolling an email address by visiting “Email Alerts” in the “Shareholder Services” section of Sprout Social’s Investor website at https://investors.sproutsocial.com/.

Social Media Profiles

www.twitter.com/SproutSocial
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial



Contact
Media:
Kristin Johnson
Sprout Social
Email: [email protected]
Phone: (312) 281-2073

Investors:
Jason Rechel
Sprout Social
Email: [email protected]
Phone: (773) 570-4892

EDTECHX HOLDINGS ACQUISITION CORP. II ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING

London, UK, Dec. 10, 2020 (GLOBE NEWSWIRE) — EdtechX Holdings Acquisition Corp. II (Nasdaq: EDTXU) (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit. The units will commence trading tomorrow, December 11, 2020, on The Nasdaq Capital Market under the symbol “EDTXU”. Each unit consists of one share of the Company’s Class A common stock, $0.0001 par value per share (“Class A Common Stock”), and one-half of one redeemable warrant (“Warrant”) with each whole Warrant entitling the holder to purchase one share of Class A Common Stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A Common Stock and Warrants are expected to be traded on The Nasdaq Capital Market under the symbols “EDTX”, and “EDTXW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

The underwriters have been granted a 45-day option to purchase up to an additional 1,500,000 units offered by the Company to cover over-allotments, if any.

The offering is expected to close on or about December 15, 2020, subject to customary closing conditions.

Jefferies LLC is acting as the sole book-running manager of the offering and Macquarie Capital is acting as the lead manager of the offering.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission on December 10, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at [email protected]. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EdtechX Holdings Acquisition Corp. II

EdtechX Holdings Acquisition Corp. II is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to any particular industry or geographic region, although the Company initially intends to focus on target businesses in the education, training, reskilling, human capital and education technology industries.  EdtechX Holdings Acquisition Corp. II is led by its founders, Charles McIntyre, Executive Chairman and Chief Investment Officer, and Benjamin Vedrenne-Cloquet, Chief Executive Officer.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the initial public offering, the anticipated use of the proceeds thereof and the search for an initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements, including those set forth in the risk factors section of the prospectus used in connection with the Company’s initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Contact:



Investor and Media Relations:
Global
Citigate Dewe Rogerson
Christen Thomson
[email protected]

North America
SPAC Alpha IR+
Chris Tyson / Doug Hobbs
[email protected]
949-491-8235



AGF Management Limited Reports Preliminary Highlights to Fourth Quarter Net Sales and Financial Results

TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) — AGF Management Limited (AGF or the Company) (TSX:AGF.B) today announced preliminary unaudited highlights for the fourth quarter ended November 30, 2020. All figures in this release are approximate due to the preliminary nature of the announcement.

AGF recorded retail mutual fund net sales for the month ended November 30, 2020 of $82 million. AGF has continued to record net sales into December, with retail net sales of $15 million as at December 9, 2020.

For the quarter ended November 30, 2020, AGF’s retail mutual fund net sales were $66 million, compared to net redemptions of $181 million in Q4 2019. Retail mutual fund gross sales improved 35% year-over-year.

AGF estimates after tax earnings from its private alternatives business will increase from $0.01 per share in Q3 2020 to approximately $0.07 per share in Q4 2020. The increase relates primarily to higher LP investment returns and related carried interest income.

Selling, general & administrative expenses (SG&A) is expected to be within guidance of $175 million for the year.

“2020 has been a difficult year and despite the challenges, we have continued to work in the interest of our stakeholders,” said Kevin McCreadie, Chief Executive Officer and Chief Investment Officer, AGF. “We continue to execute on a client-oriented plan across all global client channels, including retail, and in private alternatives.”

AGF will release its complete financial results for Q4 2020 on Wednesday, January 27, 2021 at approximately 8:00 a.m. ET.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, private alternatives and high-net-worth businesses focused on providing an exceptional client experience. AGF’s suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.

AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With over $38 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

AGF Management Limited shareholders, analysts and media, please contact:

Adrian Basaraba

Senior Vice-President and Chief Financial Officer
416-865-4203, [email protected]   

Baoqin Guo

Vice-President, Finance
416-865-4228, [email protected]

Caution Regarding Forward-Looking Statements

This press release includes forward-looking statements about certain of the Company’s expected financial performance and business operations. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as ‘expects,’ ‘estimates,’ ‘anticipates,’ ‘intends,’ ‘plans,’ ‘believes’ or negative versions thereof and similar expressions, or future or conditional verbs such as ‘may,’ ‘will,’ ‘should,’ ‘would’ and ‘could.’ In addition, any statement that may be made concerning future financial performance (including income, revenues, earnings or growth rates), ongoing business strategies or prospects, fund performance, and possible future action on our part, is also a forward-looking statement. Forward-looking statements are based on certain factors and assumptions, including expected growth, results of operations, business prospects, business performance and opportunities. While we consider these factors and assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about our operations, economic factors and the financial services industry generally. They are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied by forward-looking statements made by us due to, but not limited to, important risk factors such as level of assets under our management, volume of sales and redemptions of our investment products, performance of our investment funds and of our investment managers and advisors, client-driven asset allocation decisions, pipeline, competitive fee levels for investment management products and administration, and competitive dealer compensation levels and cost efficiency in our investment management operations, as well as general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, taxation, changes in government regulations, unexpected judicial or regulatory proceedings, technological changes, cybersecurity, the possible effects of war or terrorist activities, outbreaks of disease or illness that affect local, national or international economies (such as COVID-19), natural disasters and disruptions to public infrastructure, such as transportation, communications, power or water supply or other catastrophic events, and our ability to complete strategic transactions and integrate acquisitions, and attract and retain key personnel. We caution that the foregoing list is not exhaustive. The reader is cautioned to consider these, and other factors carefully and not place undue reliance on forward-looking statements. Other than specifically required by applicable laws, we are under no obligation (and expressly disclaim any such obligation) to update or alter the forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete discussion of the risk factors that may impact actual results, please refer to the ‘Risk Factors and Management of Risk’ section of the 2019 Annual MD&A.



Schwab Declares Preferred Stock Dividend

Schwab Declares Preferred Stock Dividend

SAN FRANCISCO–(BUSINESS WIRE)–
The Board of Directors of The Charles Schwab Corporation has declared a semi-annual dividend on the outstanding Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series A in the amount of $35 per share. The dividend is payable February 1, 2021 to stockholders of record at the close of business on January 15, 2021.

About Charles Schwab

The Charles Schwab Corporation (NYSE: SCHW) is a leading provider of financial services, with 29.0 million active brokerage accounts, 2.1 million corporate retirement plan participants, 1.5 million banking accounts, and $5.9 trillion in client assets as of October 31, 2020. Through its operating subsidiaries, the company provides a full range of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services to individual investors and independent investment advisors. Its broker-dealer subsidiaries, Charles Schwab & Co., Inc., TD Ameritrade, Inc. and TD Ameritrade Clearing, Inc., (members SIPC, www.sipc.org), and their affiliates offer a complete range of investment services and products including an extensive selection of mutual funds; financial planning and investment advice; retirement plan and equity compensation plan services; referrals to independent fee-based investment advisors; and custodial, operational and trading support for independent, fee-based investment advisors through Schwab Advisor Services. Its primary banking subsidiary, Charles Schwab Bank, SSB (member FDIC and an Equal Housing Lender), provides banking and lending services and products. More information is available at www.aboutschwab.com.

TD Ameritrade, Inc. and TD Ameritrade Clearing, Inc. are separate but affiliated companies and subsidiaries of TD Ameritrade Holding Corporation. TD Ameritrade Holding Corporation is a wholly owned subsidiary of The Charles Schwab Corporation. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank.

MEDIA:

Mayura Hooper

Charles Schwab

Phone: 415-667-1525

INVESTORS/ANALYSTS:

Jeff Edwards

Charles Schwab

Phone: 415-667-1524

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Albany International Declares Dividend

Albany International Declares Dividend

ROCHESTER, N.H.–(BUSINESS WIRE)–
The Board of Directors of Albany International Corp. (NYSE: AIN) today declared a quarterly dividend of $0.20 per share on the Company’s Class A and Class B Common Stock, payable January 8, 2021, to shareholders of record on December 22, 2020.

About Albany International Corp.

Albany International is a leading developer and manufacturer of engineered components, using advanced materials processing and automation capabilities, with two core businesses. Machine Clothing is the world’s leading producer of fabrics and process felts used in the manufacture of all grades of paper products. Albany Engineered Composites is a rapidly growing designer and manufacturer of advanced materials-based engineered components for jet engine and airframe applications, supporting both commercial and military platforms. Albany International is headquartered in Rochester, New Hampshire, operates 23 plants in 11 countries, employs more than 4,000 people worldwide, and is listed on the New York Stock Exchange (Symbol AIN). Additional information about the Company and its products and services can be found at www.albint.com.

John Hobbs

603-330-5897

[email protected]

KEYWORDS: New Hampshire United States North America

INDUSTRY KEYWORDS: Aerospace Manufacturing Textiles Engineering Chemicals/Plastics

MEDIA:

Logo
Logo

Burnham Benefits Insurance Services, Inc. Announces Agreement to Enter Into Partnership With BRP Group, Inc.

IRVINE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Burnham Benefits Insurance Services, Inc. (“BBIS”), Burnham Gibson Wealth Advisors, Inc. (“BGWA”) and Burnham Risk and Insurance Solutions, LLC (“BRIS”) (collectively, “Burnham”), a full-service provider of employee benefits consulting, retirement consulting, wealth management and insurance brokerage services to mid-size and large enterprises, announced that it has agreed to enter into a partnership with Baldwyn Krystyn Sherman Partners, LLC (“BKS-Partners”), the middle-market indirect subsidiary of BRP Group, Inc. (“BRP Group”) (NASDAQ: BRP), to become part of BRP Group’s middle-marketing operating group. BRP Group is a rapidly growing independent insurance distribution firm delivering tailored insurance solutions. The Partnership, BRP Group’s nomenclature for a strategic acquisition, is expected to close December 31, 2020, subject to certain closing conditions.

With annual revenues of approximately $52.61 million, Burnham (#79 in Business Insurance’s “Top 100” list of largest U.S. brokers) represents one of the largest Partnerships in BRP Group’s history. Burnham President and CEO Kristen Allison will serve as Regional President, and BGWA President Darin Gibson and BRIS COO Sara Owens will serve as Managing Partners within BRP Group’s middle-market operating group. Following this Partnership, Burnham will maintain its brand and operate as “Burnham – A Baldwin Risk Partner.”

Over its 25-year history, Burnham has delivered an impressive track record of revenue growth. This Partnership, which brings with it approximately 130 colleagues, marks BRP Group’s entrance into some of the largest MSAs in California, including Los Angeles, Orange County and Sacramento, and further expands BRP Group’s presence in the San Francisco area. Burnham provides a full scope of strategic and tactical solutions centered around a client-first consulting approach. Burnham has cultivated a large and broad spectrum of clients including some of the most respected Consumer, Technology, Health Care, Non-Profit, Professional and Financial Services companies. Burnham has also become a leader in the Public Sector, with clients ranging from K-12 Schools and Community Colleges to Cities, Counties and Special Districts.

“We work and think differently at Burnham, which is why we have been able to so successfully and rapidly grow our business,” said Kristen Allison, President and CEO of Burnham. “With BRP Group, Burnham will be uniquely equipped to solve the challenging problems that businesses and organizations face today, now with a national footprint for coverage and capabilities. Burnham and BRP Group have a remarkable similarity in development of culture and importance of values; both have a client-first, transparent approach that embraces innovation, collaboration, and creativity. We are elated by the opportunity to deepen our client and colleague commitment to excellence.”

“We have made major strides in expanding our middle-market segment’s capabilities and reach, and partnering with Burnham is a fantastic addition to an incredible 2020 for BRP Group,” said Trevor Baldwin, CEO of BRP Group. “Burnham has delivered impressive growth through its breadth of resources and unparalleled client service, and it will become a vital part of our middle-market organization, further expanding our footprint to some of the largest markets in the U.S. Kristen and her talented team prioritize client service above all else, while nurturing a socially-responsible and accountable culture that is in sync with what we have built at BRP. BGWA, totaling nearly $2.5 billion in AUM (assets under management)2, offers tremendous scale in a highly complementary and synergistic business line in which we are excited to continue our investment and growth. Burnham’s commitment to building culture is evidenced by their recently being named #1 in Business Insurance’s list of “2020 Best Places to Work in Insurance.” We’re proud and excited to have Burnham join the BRP family as we continue to rapidly expand throughout the U.S.” MarshBerry acted as exclusive financial advisor to Burnham in the transaction.

ABOUT
BURNHAM BENEFITS INSURANCE SERVICES
, INC.

Burnham Benefits Insurance Services, Inc. is a full-service strategic employee benefits consulting, and brokerage firm based in Irvine, California, with eight offices offering comprehensive client-first strategic solutions. We have cultivated a unique culture that allows our leadership to easily adapt and create customized programs that fit clients’ best interests. Burnham Benefits’ cadre of highly skilled industry professionals and strategic partnerships provide unmatched personal service. We hold national recognition as one of the Best Places to Work in Insurance by Business Insurance magazine for the eighth year and counting, and over the last decade consistently ranks as one of the Best Places to Work by the Orange County Business Journal, North Bay Business Journal, and Los Angeles Business Journal. For more information, visit www.BurnhamBenefits.com

ABOUT BURNHAM RISK AND INSURANCE SOLUTIONS, LLC.

Burnham Risk and Insurance Solutions, LLC offers property and casualty consulting, utilizing a unique approach to develop and negotiate tailored risk management plans that protect you and your business. Our expertise, advanced technology solutions, and the ability to put our clients first differentiate us in the industry. Burnham Risk’s expertise, advanced technology solutions, and client-first approach allow us to provide the best commercial and personal line coverage. For more information, visit www.BurnhamRisk.com.

ABOUT BURNHAM GIBSON WEALTH ADVISORS, INC.

Burnham Gibson Wealth Advisors, Inc. is an independent registered investment adviser based in Irvine, California offering comprehensive wealth management and corporate retirement consulting solutions to help clients with their financial goals and the needs of their workforce. With diverse experience and advanced technology, Burnham Gibson takes a client-first approach in helping corporate and individual clients accumulate wealth, manage risk and plan for the future. For more information, visit www.BurnhamGibson.com

ABOUT BRP GROUP, INC.

BRP Group, Inc. (NASDAQ: BRP) is a rapidly growing independent insurance distribution firm delivering tailored insurance and risk management insights and solutions that give our clients the peace of mind to pursue their purpose, passion and dreams. We are innovating the industry by taking a holistic and tailored approach to risk management, insurance and employee benefits, and support our clients, Colleagues, Insurance Company Partners and communities through the deployment of vanguard resources and capital to drive our growth. BRP represents over 500,000 clients across the United States and internationally. For more information, please visit www.BaldwinRiskPartners.com. Learn more about BKS-Partners at www.bks-partners.com.
        
NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which represent BRP Group’s expectations or beliefs concerning future events. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or BRP Group’s strategies or expectations, including those about this Partnership. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.

Factors that could cause actual results or performance to differ from the expectations expressed or implied in such forward-looking statements include, but are not limited to, those described under the caption “Risk Factors” in BRP Group’s Annual Report on Form 10-K for the year ended December 31, 2019, BRP Group’s Quarterly Reports on Form 10-Q for the three months ended March 31, 2020, and BRP Group’s other filings with the SEC, which are available free of charge on the Securities and Exchange Commission’s website at: www.sec.gov, including those risks and other factors relevant to BRP Group’s completion and integration of this Partnership, matters assessed in BRP Group’s due diligence, the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements, the risk that necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated, the risk that this Partnership will not be consummated in a timely manner, risks related to the disruption of management time from ongoing business operations due to this Partnership, the business, financial condition and results of operations of BRP Group or this Partner, or both, and factors related to the potential effects of the COVID-19 pandemic on BRP Group’s business, financial condition and results of operations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to BRP Group or to persons acting on behalf of BRP Group are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and BRP Group does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

CONTACTS

INVESTOR RELATIONS
– BRP GROUP

(813) 259-8032 | [email protected]

PRESS
– BRP GROUP

Rachel Carr, Marketing Director

Baldwin Risk Partners

(813) 418-5166 | [email protected]

Burnham Benefits

Kristen Allison, President & CEO

(949) 252-4580 | [email protected]

Burnham Gibson Wealth
Advisors

Darin Gibson, President

(949) 833-5738 | [email protected]

Burnham Risk

Sara Owens, Managing Partner

(213) 788-7559 | [email protected]


1

Calculated as revenue attributable to the acquired business for the most recent twelve-month period prior to acquisition by BRP Group based on Quality of Earnings Review. Excludes any unowned acquired revenue from acquisitions made by such acquired business in the last twelve months prior to the acquisition.


2

Burnham Gibson Wealth Advisors, Inc. 2020 Form ADV.



SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.

PR Newswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. (“NEOS” or the “Company”) (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by Aytu BioScience, Inc. (“Aytu”) (NASDAQ: AYTU).  Under the terms of the merger agreement, NEOS shareholders will be entitled to receive 0.1088 shares of Aytu common stock for each NEOS share that they own, representing implied per-share merger consideration of a mere $0.74 based upon Aytu’s December 9, 2020 closing price of $6.83.  Upon closing of the proposed transaction, NEOS shareholders will only own approximately 30% of the combined company.


If you own NEOS shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


http://www.weisslawllp.com/NEOS/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether NEOS’ board acted in the best interest of NEOS’ public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the sales process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed.  Notably, at least one analyst has set a price target for the Company as high as $10 per share, over 13 times the value of the implied per-share merger consideration.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected].

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-neos-therapeutics-inc-301190865.html

SOURCE WeissLaw LLP

Homepoint Partners with Appian to Accelerate I.T. Through Low-Code Automation Technology

Low-code Automation Platform Delivers an Enhanced Customer Experience with Faster Loan Processing and Approvals

PR Newswire

ANN ARBOR, Mich., Dec. 10, 2020 /PRNewswire/ — Homepoint, one of the nation’s leading mortgage originators and servicers, today announced it selected the Appian (NASDAQ: APPN) Low-Code Automation Platform. The shift to low-code represents a significant technology transformation for Homepoint, enabling rapid scalability and flexibility to accommodate the needs of partners and customers while maintaining a low-cost structure.

“The ability to evolve technology faster is becoming more important within the operations of every business; things are changing at a rapid pace,” said Phil Shoemaker, President of Originations at Homepoint. “By integrating Appian’s low-code technology, this gives Homepoint a huge advantage over our competition, because it allows us to more directly empower the business to rapidly change workflow and business processes without going through a costly and cumbersome software development process that often delivers only a portion of what the business needs.”

The adoption of low-code technology enables Homepoint to deliver a more refined and seamless loan origination and servicing experience in a variety of ways:

  • Faster loan processing – Drastically reduces processing time from hours to minutes, giving the ability to respond to issues quickly and provide brokers and customers accelerated certainty on applications.
  • Real-time visibility – Provides easy-to-use dashboards and interfaces giving loan officers and processors the ability to monitor processes whenever they want.
  • Improved data integrity and accessibility – Offers reliable applications that decrease human error and allow Homepoint to learn more about customer preferences by analyzing data to help brokers take anticipatory steps to retain their business.

“We are excited to see low-code automation at the forefront of the mortgage industry,” said Mike Beckley, CTO and Founder at Appian. “Low-code development is the future of lending, as companies opt for a simple, seamless digitized solution that maximizes speed and flexibility over big-budget monolithic loan origination systems. The combination of low-code speed and powerful process automation allows fast-growing and forward-thinking companies like Homepoint to not only be competitive but lead in their industries.”

To learn more about how Homepoint is redefining the homebuying and homeownership experience, visit homepoint.com.

About Homepoint
Homepoint is a leading mortgage originator and servicer redefining the homebuying and homeownership experience. The company supports successful homeownership as a crucial element of broader financial security and well-being, delivering a seamless and less stressful homebuying experience. Founding in 2015 and headquartered in Ann Arbor, Michigan, Homepoint works closely with a nationwide network of over 5,500 mortgage broker and correspondent partners with deep knowledge and expertise about the communities and customers they serve. Today, Homepoint is the nation’s third-largest wholesale mortgage lender and 9th-largest nonbank mortgage lender.

Home Point Financial Corporation d/b/a Homepoint. NMLS No. 7706 (For licensing information, go to: http://www.nmlsconsumeraccess.org). Home Point Financial Corporation does not conduct business under the name, “Homepoint” in IL, KY, LA, MD, NY, or WY. In these states, the company conducts business under the full legal name, Home Point Financial Corporation. 2211 Old Earhart Road, Suite 250, Ann Arbor, MI 48105. Toll-Free Tel: 888-616-6866. Learn more at Homepoint.com.

About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications. Many of the world’s largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance. www.appian.com 


Media Contacts:


Homepoint


Appian

Brad Pettiford

Nicole Greggs

Director of Public Relations 

Director – Media Relations

(734) 356-3092

(703) 260-7868


[email protected]
 


[email protected] 

 

Cision View original content:http://www.prnewswire.com/news-releases/homepoint-partners-with-appian-to-accelerate-it-through-low-code-automation-technology-301190874.html

SOURCE Homepoint

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

— sBLA Currently Under Review by the U.S. FDA for Full Marketing Approval in mTNBC —

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in this patient population with traditionally poor outcomes.

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate that is indicated in the U.S. for the treatment of adult patients with mTNBC who have received at least two prior therapies for metastatic disease. Trodelvy received accelerated approval for this patient population in April 2020, based on objective response rate and duration of response results observed in a single-arm, multicenter Phase 2 study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The Trodelvy U.S. Prescribing Information has a BOXED WARNING for severe neutropenia and severe diarrhea; see below for Important Safety Information.

Based on the overall efficacy and safety results with Trodelvy in the Phase 3 ASCENT trial, Gilead has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for full approval as a treatment for adult patients with mTNBC who have received at least two prior therapies.

“These new data and analyses from the ASCENT trial continue to demonstrate the benefits of Trodelvy in a difficult-to-treat patient population and reinforce the role of Trodelvy as an important treatment option for mTNBC patients,” said Loretta M. Itri, Chief Medical Officer of Immunomedics, a wholly owned subsidiary of Gilead.

“We look forward to working with the FDA in their review of the sBLA submission for Trodelvy in mTNBC, and partnering with the agency, clinical trial investigators and participants as we build on the work of Immunomedics and continue to study Trodelvy in other cancers with unmet medical need,” said Daejin Abidoye, Senior Vice President, Head of Oncology, Gilead Sciences.

Data and analyses from the Phase 3 ASCENT trial being presented at SABCS 2020 include:

  • An exploratory analysis demonstrating overall survival, objective response rate and progression-free survival with Trodelvy versus chemotherapy in brain metastases-negative mTNBC patients irrespective of Trop-2 expression levels. Trop-2 receptors are expressed on the surface of many epithelial tumor cells and linked to poor prognosis, including decreased survival. (Abstract #GS3-06)
  • An exploratory analysis demonstrating tumor response, progression-free survival and overall survival with Trodelvy versus chemotherapy in a subset of mTNBC patients with stable brain metastases of limited sample size (Trodelvy, N=32; TPC, N=29). (Abstract #PD13-07)
  • Additional safety data on Trodelvy in mTNBC patients with reduced uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) activity. Patients who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of treatment with Trodelvy. (Abstract #PS11-09)

About Triple-Negative Breast Cancer (TNBC)

TNBC is an aggressive type of breast cancer, accounting for up to 20% of all breast cancers. The disease is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited human epidermal growth factor receptor 2 (HER2). Medicines targeting these receptors therefore are not typically effective in treating TNBC. There is currently no approved standard of care for people with previously treated metastatic TNBC.

About the ASCENT Trial

The Phase 3, international, multi-center, randomized confirmatory trial enrolled more than 500 patients with relapsed/refractory, metastatic triple-negative breast cancer who had received at least two prior therapies for metastatic disease. Patients were randomized to receive either Trodelvy or a chemotherapy chosen by the patients’ treating physicians. The primary endpoint of the study was progression-free survival. Secondary endpoints include overall survival, objective response rate, duration of response, time to onset of response, and other measures of safety and tolerability. More information about ASCENT is available at http://clinicaltrials.gov/show/NCT02574455.

About Trodelvy

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated in the U.S. for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Trodelvy binds to the cell-surface protein Trop-2 and delivers the anti-cancer drug SN-38 to kill cancer cells.

Trodelvy received accelerated approval as a treatment for adult patients with mTNBC who have received at least two prior therapies, based on results of a single-arm, multicenter Phase 2 study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

In addition to multiple ongoing studies of Trodelvy in triple-negative breast cancer, Trodelvy is being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.

Important Safety Information for Trodelvy

WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY can cause severe or life-threatening neutropenia. Withhold TRODELVY for absolute neutrophil count (ANC) below 1500/mm3 on Day 1 of any cycle or ANC below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever.

Monitor blood cell counts periodically during treatment. Consider Granulocyte Colony-Stimulating Factor (G-CSF) for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.

  • Dose modifications may be required due to neutropenia. Febrile neutropenia occurred in 6% (24/408) of patients treated with TRODELVY, including 8% (9/108) of patients with mTNBC after at least 2 prior therapies. Less than 1% (1/408) of patients had febrile neutropenia leading to permanent discontinuation. The incidence of Grade 1-4 neutropenia was 64% in patients with mTNBC (n=108). In all patients treated with TRODELVY (n=408), the incidence of Grade 1-4 neutropenia was 54%; Grade 4 neutropenia occurred in 13%. Less than 1% (2/408) of patients permanently discontinued treatment due to neutropenia.

Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed.Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses.

  • Diarrhea occurred in 63% (68/108) of patients with mTNBC and 62% (254/408) of all patients treated with TRODELVY. In each population, events of Grade 3-4 occurred in 9% (10/108) of mTNBC patients and 9% (36/408) of all patients treated with TRODELVY. Four out of 408 patients (<1%) discontinued treatment because of diarrhea. Neutropenic colitis was observed in 2% (2/108) of patients in the mTNBC cohort and 1% of all patients treated with TRODELVY.

Contraindications: Severe hypersensitivity reaction to TRODELVY.

Hypersensitivity

  • TRODELVY can cause severe and life-threatening hypersensitivity, including anaphylactic reactions. Hypersensitivity reactions occurred within 24 hours of dosing in 37% (151/408) and Grade 3-4 hypersensitivity occurred in 1% (6/408) of all patients treated with TRODELVY (n=408). The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 1% (3/408).
  • Pre-infusion medication for patients receiving TRODELVY is recommended. Observe patients closely for infusion-related reactions during each TRODELVY infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use.

Nausea and Vomiting

  • TRODELVY is emetogenic. Nausea occurred in 69% (74/108) of patients with mTNBC and 69% (281/408) of all patients treated with TRODELVY. Grade 3 nausea occurred in 6% (7/108) and 5% (22/408) of these populations, respectively. Vomiting occurred in 49% (53/108) of patients with mTNBC and 45% (183/408) of all patients treated with TRODELVY. Grade 3 vomiting occurred in 6% (7/108) and 4% (16/408) of these patients, respectively.
  • Premedicate with a 2- or 3-drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV).
  • Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting at the time of scheduled treatment administration and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Use in Patients with Reduced UGT1A1 Activity

  • Individuals who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia and may be at increased risk for other adverse events following initiation of TRODELVY treatment. Closely monitor patients with reduced UGT1A1 activity for severe neutropenia. The appropriate dose for patients who are homozygous for UGT1A1*28 is not known and should be considered based on individual patient tolerance to treatment.
  • In 84% (343/408) of patients who received TRODELVY (up to 10 mg/kg on Days 1 and 8 of a 21-day cycle) and had retrospective UGT1A1 genotype results available, the incidence of Grade 4 neutropenia was 26% (10/39) in patients homozygous for the UGT1A1*28 allele, 13% (20/155) in patients heterozygous for the UGT1A1*28 allele, and 11% (16/149) in patients homozygous for the wild-type allele.

Embryo-Fetal Toxicity

  • TRODELVY contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
  • Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose of TRODELVY.

Adverse Reactions

Most common adverse reactions (incidence >25%) in patients with mTNBC are nausea (69%), neutropenia (64%), diarrhea (63%), fatigue (57%), anemia (52%), vomiting (49%), alopecia (38%), constipation (34%), rash (31%), decreased appetite (30%), abdominal pain (26%), and respiratory infection (26%).

Please see full Prescribing Information, including BOXED WARNING.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Gilead Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical studies involving Trodelvy, and the possibility that Gilead may be unable to initiate and complete future studies involving Trodelvy in the anticipated timelines or at all. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. Prescribing Information for TRODELVY, including BOXED WARNING, is available at www.gilead.com.

TRODELVY, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Monica Tellado, Investors

(650) 522-5132

Marian Cutler, Media

(973) 517-0519

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Hospitals Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

EVBox Group to Become Public Company via Business Combination with TPG Pace Beneficial Finance

EVBox Group to Become Public Company via Business Combination with TPG Pace Beneficial Finance

EVBox Group to Gain Access to Growth Capital to Fuel Global Expansion

EVBox Group’s Leadership Position in European EV Charging Solutions is Aligned with TPG Pace Beneficial Finance’s Commitment to Advancing High-Growth, ESG-Focused Companies Globally

ENGIE to Retain 40+% Ownership

Institutional Investors Including Funds and Accounts Managed by BlackRock, Inclusive Capital Partners, Neuberger Berman Funds and Wellington Management to Invest Additional $225 Million of Equity Through Private Placement at Closing

EVBox Group to be Listed on the NYSE Following Close Expected Late Q1-2021

SAN FRANCISCO & PARIS & AMSTERDAM–(BUSINESS WIRE)–
TPG Pace Beneficial Finance Corp. (NYSE: TPGY.U, TPGY, TPGY WS) (“TPG Pace”), a publicly traded special purpose acquisition company (“SPAC”) formed by TPG that is focused on high-growth companies with strong environmental, social and governance (“ESG”) principles, today announced it has entered into a definitive agreement with ENGIE New Business S.A.S., a wholly owned subsidiary of ENGIE S.A. (“Engie”), a multi-national utility with headquarters in France, to acquire its subsidiary EV Charged B.V. (the “Company”, “EVBox” or “EVBox Group”) for a combination of cash and equity. EVBox is a leading global provider of smart charging solutions for electric vehicles (“EV”) with Europe’s largest installed base of charging solutions and the most advanced cloud-based software offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210006109/en/

(Photo: Business Wire)

(Photo: Business Wire)

The transaction is expected to provide EVBox with significant growth capital to expand its reach globally, with focus on Europe and North America, and broaden its technology portfolio, positioning the company to drive and benefit from the growing wave of EV adoption. Following the transaction, EVBox expects to have more than $425 million of cash on its balance sheet, including a portion of the proceeds of TPG Pace’s fully committed Private Investment in Public Equity (“PIPE”) of $225 million, $100 million from TPG Pace’s Forward Purchase Agreements and $350 million of cash held in TPG Pace’s trust account. EVBox also expects to benefit from the partnership with TPG, which has a proven track record of assisting high-growth technology companies successfully transition to the public equity markets. ENGIE will retain a more than 40 percent ownership stake in the Company and expects to continue as a key partner of the Company following the transaction.

“For over a decade, EVBox has been a pioneer in the electric vehicle charging industry, developing and launching innovative software propositions along with award-winning charging stations. We are now scaled for further global expansion and to take a leading role in the anticipated acceleration of EV adoption as we work towards a future where everyday transportation is electric, emission-free and sustained by a clean charging infrastructure,” said Kristof Vereenooghe, President and CEO of EVBox Group. “The global support for this future is ever more evident as world leaders convene in two days for the Climate Ambition Summit to set even more aggressive national goals. With our new partners at TPG, support from ENGIE and a prestigious group of new investors, we anticipate being well positioned to help meet these goals by accelerating product development and providing end-to-end solutions to our expanding customer base, particularly in North America.”

“TPG’s position as one the first movers in both SPACs and impact investing gives us a distinct advantage to help select purpose-driven and disruptive companies as they transition to the public equity markets. We believe that EVBox is a perfect fit with our investment thesis, and we are positioned to help accelerate the growth of this market-leading impact company by providing significant capital and capabilities to assist its mission,” said Karl Peterson, of TPG Pace Group. “We look forward to collaborating with Kristof and the extremely talented EVBox team on the next phase of their growth story and using our network to help them expand on both sides of the Atlantic.”

EVBox is focused on solving the unique demands of customers, businesses and drivers in the dynamic EV industry, and driving innovations that anticipate future market needs. EVBox offers a portfolio of both hardware and enterprise software solutions and has built the industry’s largest installed base of EV charging solutions, with more than 190,000 charge ports across 70 countries. The Company’s growth is driven by sales of equipment as well as recurring-revenue software subscriptions, services and transaction processing fees. EVBox’s open architecture SaaS platform, Everon, serves as the backbone of the offering, with a cloud-native, charging management solution that can support both EVBox and third-party hardware. The Everon software enables new monetization opportunities for charging station owners, supports dynamic load management and enables integration with other software via APIs. EVBox’s offering also includes a complete suite of award-winning AC level 2 and DC fast and ultra-fast, smart charging stations, ranging from 3 to 350 kW, all served by mobility services offered through partners worldwide. EVBox is also a founding member of the Open Charge Alliance and its offerings comply with all Open Charge Point Protocols.

Michael MacDougall, President of TPG Pace, said, “We’ve been closely following this sector and have come to appreciate that charging solutions in Europe are several years ahead of the U.S. and poised to experience explosive growth from the green initiatives of governments, major corporations, automotive OEMs and consumers, alike. EVBox has an enviable position as a clear leader across Europe with the best charging station offering and a clearly differentiated cloud-based software solution that will be an even more important factor in the next stage of this critical market’s evolution.”

“As part of its refocus on renewables and clean technology, ENGIE acquired EVBox in 2017. Since then, EVBox has been at the forefront in providing EV charging solutions in Europe,” said Yves Le Gélard, Executive Vice President, Chief Digital Officer at ENGIE. “We have been impressed by EVBox’s pace of technology development and look forward to the Company’s continued evolution as an independent publicly traded company. The acquisition of EVBox enabled ENGIE to quickly step into the electric charging market, and to build strong positions across Europe. ENGIE now plans to focus its efforts towards design and operation of EV charging infrastructures. eMobility remains at the core of our strategy and we look forward to EVBox being a strong partner to ENGIE.”

TPG Pace worked extensively with its affiliate, Y Analytics, to measure and quantify the Company’s ESG performance and impact. Y Analytics is a distinctive capability in the ESG and impact investing marketplace, leveraging research and fact-based evidence to generate value-centric ESG and impact performance insights for the investment process. Y Analytics concluded that EVBox presents a transformational opportunity for positive environmental impact, estimating that over the next five years, EVBox’s product offering has the potential to catalyze EV adoption at a rate that averts more than 19 million metric tons of CO2 over the lifetime of the vehicles. Following the transaction, Y Analytics expects to continue to work with EVBox to help the Company effectively communicate and track its ESG performance and impact.

TPG has had a long-standing commitment to fostering ESG performance in its portfolio and has grown The Rise Fund, its $5 billion impact investing platform, to become the largest of its kind in the private markets. The firm has an extensive track-record of identifying markets at inflection points and supporting disruptive high-growth companies poised to catalyze or accelerate structural changes in those markets. TPG also has deep experience transitioning companies from the private to public market, having taken 55 companies public over the past 10 years. With that expertise, the firm launched the TPG Pace Group in 2015 to sponsor SPACs and other permanent capital solutions for companies and has since successfully completed five SPAC IPOs to date.

Transaction Summary

The business combination values EVBox at an implied $969 million enterprise value. Upon transaction closing, and assuming no redemptions by TPG Pace stockholders, EVBox is expected to have approximately $425 million in cash, and a total pro-forma equity value of approximately $1.394 billion.

TPG Pace raised capital through an initial public offering for the purpose of entering into a merger, stock purchase or similar business combination with one or more businesses. The combined company will be renamed EVBox Group. Its common shares and warrants are expected to be listed on the New York Stock Exchange (the “NYSE”) under the ticker symbols “EVB” and “EVB WS” Upon closing, EVBox will have a nine person board and a majority of independent directors.

Cash proceeds raised in the transaction will be used to fund operations, support growth and notably pay cash consideration of up to $180 million to ENGIE.

ENGIE expects that the transaction will result in a net debt decrease of ca 0.2 bn€ and EVBox no longer being consolidated in its accounts, with ENGIE’s remaining approximate 40+% shareholding accounted by the equity method.

The transaction is subject to approval by the TPG Pace shareholders and other customary closing conditions. Both ENGIE and TPG Pace have all other required approvals for the proposed transaction. The transaction is expected to close late Q1 2021.

Advisors

Nomura Greentech acted as financial advisor to ENGIE. Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and TPG Capital BD, LLC acted as capital markets advisors and PIPE placement agents to TPG Pace. Linklaters LLP acted as the legal advisor to ENGIE and Vinson & Elkins L.L.P. acted as the legal advisor to TPG Pace.

Investor Webcast and Presentation Information

At 5:00 pm EST on December 10, 2020, TPG Pace will be holding an investor conference call. For those who wish to participate, the domestic toll-free access number is +1 833 470 1428 and the international toll-free access number is +1 404 975 4839. Once connected with the operator, please provide the Conference ID number of 529691 and request access to the EVBox Transaction Announcement Investor Call.

A replay of the call will also be available from 6:00 pm EST on December 10, 2020 to 11:59 pm EST on January 10, 2021. To access the replay, go to https://www.netroadshow.com/ and enter the Entry Code: Capital58.

All investor materials, including a copy of the investor presentation, can be found at https://www.tpg.com/pace-beneficial-finance.

About EVBox Group

Founded in 2010, EVBox Group is a leading global provider of EV charging technologies, empowering forward-thinking businesses to drive sustainable mobility, by offering integrated, flexible and scalable EV charging solutions. As a technology pioneer, EVBox Group has been at the forefront of many industry-defining developments including actively promoting smart charging technologies, price transparency and free roaming of charging infrastructure across borders. EVBox Group always seeks to collaborate closely with industry partners and public organizations, with the goal of providing customers and drivers the best charging experience. EVBox Group has been a pioneer and promoter of open standards and offers its drivers a network of more than 190,000 charge ports and its site hosts a possibility to open their charging infrastructure to more than 2 million drivers. EVBox Group is active in all market segments, with customers varying from residential to workplace to retail to fleets and automakers—who all trust the company’s proven, complete charging solutions to help them efficiently and sustainably expand their business. For more information, visit evbox.com. For media questions, please reach out to [email protected].

About ENGIE

ENGIE is a global reference in low-carbon energy and services. ENGIE’s purpose (“raison d’être”) is to act to accelerate the transition towards a carbon-neutral world, through reduced energy consumption and more environmentally friendly solutions, reconciling economic performance with a positive impact on people and the planet. ENGIE relies on its key businesses (gas, renewable energy, services) to offer competitive solutions to its customers. With its 170,000 employees, its customers, partners and stakeholders, ENGIE is a community of Imaginative Builders, committed every day to more harmonious progress.

Turnover in 2019: 60.1 billion Euros. ENGIE is listed on the Paris and Brussels stock exchanges (ENGI) and is represented in the main financial indices (CAC 40, DJ Euro Stoxx 50, Euronext 100, FTSE Eurotop 100, MSCI Europe) and non-financial indices (DJSI World, DJSI Europe and Euronext Vigeo Eiris – World 120, Eurozone 120, Europe 120, France 20, CAC 40 Governance).

About TPG

TPG is a leading global alternative asset firm founded in 1992 with approximately $85 billion of assets under management and offices in Austin, Beijing, Fort Worth, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, Singapore, and Washington, DC. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth equity, real estate, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com or Twitter @TPG.

About TPG Pace Group and TPG Pace

TPG Pace Group is TPG’s dedicated permanent capital platform. TPG Pace Group has a long-term, patient, and highly flexible investor base, allowing it to seek compelling opportunities that will thrive in the public markets. TPG Pace Group has sponsored five special purpose acquisition companies (“SPACs”) and raised more than $3 billion since 2015.

TPG Pace raised $350 million in its October 2020 IPO in order to seek a business combination target that combines attractive business fundamentals with, or with the potential for strong environmental, social and governance (“ESG”) principles and practices. For more information, visit https://www.tpg.com/pace-beneficial-finance.

TPG Pace Group is also sponsoring TPG Pace Tech Opportunities (NYSE: PACE, PACE.U, PACE WS) which raised $450 million in its October 2020 IPO along with $150 million of forward purchase agreements. It is seeking a business combination with a leading technology company that complements the experience and expertise of our management team and TPG and is a business that TPG’s transformative operating skills and strategic advice can help improve. For more information, visit https://www.tpg.com/story/tpg-pace-tech-opportunities.

About Y Analytics

Y Analytics is a public benefit corporation where independent research and capital converge for good. Y Analytics bridges the divide between decision-makers and the research community, leveraging a research-based approach to help better understand the impact of capital allocation decisions. Y Analytics enables the increasing efficiency and reach of every dollar invested for impact. The organization was founded by TPG in conjunction with The Rise Fund and is headquartered in Washington, D.C. For more information, visit yanalytics.org.

Important Information for Investors and Shareholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.

In connection with the proposed business combination, Edison Holdco B.V. (“Holdco”), an affiliate of TPG Pace, will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4, which will include a prospectus of Holdco and a proxy statement of TPG Pace. Holdco and TPG Pace also plan to file other documents with the SEC regarding the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive joint proxy statement/prospectus will be mailed to the shareholders of TPG Pace. INVESTORS AND SHAREHOLDERS OF TPG PACE ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE PROPOSED BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION. Investors and shareholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about Holdco and TPG Pace once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov.

Participants in the Solicitation

Holdco, TPG Pace, ENGIE and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of TPG Pace in connection with the proposed transaction. Information about the directors and executive officers of TPG Pace is set forth in TPG Pace’s initial public offering prospectus, which was filed with the SEC on October 8, 2020. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

Forward Looking Statements

The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included herein, regarding the proposed merger of TPG Pace into New TPG Pace Beneficial Finance Corp. and the proposed acquisition of the common shares of EVBox Group by Holdco, Holdco’s, ENGIE New Business’s and TPG Pace’s ability to consummate the transaction, the benefits of the transaction and Holdco’s future financial performance following the transaction, as well as Holdco’s, ENGIE New Business’s and TPG Pace’s strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward looking statements. When used herein, including any oral statements made in connection herewith, the words “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Holdco, EVBox Group, ENGIE and TPG Pace disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. Holdco, EVBox Group, ENGIE and TPG Pace caution you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Holdco and TPG Pace. These risks include, but are not limited to, (1) the inability to complete the transactions contemplated by the proposed business combination; (2) the inability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, and the ability of the combined business to grow and manage growth profitably; (3) risks related to the rollout of EVBox Group’s business and expansion strategy; (4) consumer failure to accept and adopt electric vehicles; (5) overall demand for electric vehicle charging and the potential for reduced demand if governmental rebates, tax credits and other financial incentives are reduced, modified or eliminated; (6) the possibility that EVBox Group’s technology and products could have undetected defects or errors; (7) the effects of competition on EVBox Group’s future business; (8) the inability to successfully retain or recruit officers, key employees, or directors following the proposed business combination; (9) effects on TPG Pace’s public securities’ liquidity and trading; (10) the market’s reaction to the proposed business combination; (11) the lack of a market for TPG Pace’s securities; (12) TPG Pace’s and EVBox Group’s financial performance following the proposed business combination; (13) costs related to the proposed business combination; (14) changes in applicable laws or regulations; (15) the possibility that the novel coronavirus (“COVID-19”) may hinder TPG Pace’s ability to consummate the business combination; (16) the possibility that COVID-19 may adversely affect the results of operations, financial position and cash flows of TPG Pace, Holdco or EVBox Group; (17) the possibility that TPG Pace or EVBox Group may be adversely affected by other economic, business, and/or competitive factors; and (18) other risks and uncertainties indicated from time to time in documents filed or to be filed with the SEC by TPG Pace. Should one or more of the risks or uncertainties described herein and in any oral statements made in connection therewith occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact Holdco’s and TPG Pace’s expectations and projections can be found in TPG Pace’s initial public offering prospectus, which was filed with the SEC on October 8, 2020. In addition, TPG Pace’s periodic reports and other SEC filings are available publicly on the SEC’s website at www.sec.gov.

ADDITIONAL INFORMATION ABOUT THE BUSINESS COMBINATION AND WHERE TO FIND IT

In connection with the proposed business combination, Holdco will file a registration statement on Form F-4 and the related proxy statement/prospectus with the SEC. Additionally, Holdco and TPG Pace will file other relevant materials with the SEC in connection with the proposed merger of TPG Pace into New TPG Pace Beneficial Finance Corp. and the proposed acquisition from ENGIE of the common shares of EVBox Group by Holdco. The materials to be filed by Holdco and TPG Pace with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. Investors and security holders of TPG Pace are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed business combination because they will contain important information about the business combination and the parties to the business combination.

Media:

ENGIE

Tél. France: +33 (0)1 44 22 24 35

Email: [email protected]

ENGIEpress

EVBox:

Job Karstens

[email protected]

+31 (0)6 22 26 55 25

Madeline Vidak

[email protected]

+31 (0)6 30 71 06 93

General: [email protected]

TPG/TPG Pace

Luke Barrett

(415) 743-1550

[email protected]

Tom Johnson/Sheila Ennis

Abernathy MacGregor

(917) 747-6990/(510) 604-8027

[email protected]/ [email protected]

Investor:
ENGIE

Tél.: +33 (0)1 44 22 66 29

Email: [email protected]

KEYWORDS: Netherlands North America France United States Europe California

INDUSTRY KEYWORDS: Banking Other Energy Professional Services Hardware Alternative Energy Alternative Vehicles/Fuels Consumer Electronics Energy Technology Automotive Automotive Manufacturing Finance Manufacturing

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)